Stock Track | SIMCERE PHARMA Soars 7.87% in Morning Session on New CEO Appointment and Strong Financial Results

Stock Track03-27

SIMCERE PHARMA's stock soared 7.87% during the morning trading session on Friday, reflecting strong investor confidence in the company's strategic direction.

The surge follows the company's announcement that Zhou Yunshu, the former Chairman of HENGRUI PHARMA, has officially joined SIMCERE PHARMA as Chief Executive Officer. The company highlighted Zhou's extensive experience in managing domestic pharmaceutical enterprises and his proven track record at HENGRUI PHARMA, where he successfully drove the transition toward innovative drug development.

Investors were also encouraged by SIMCERE PHARMA's recently released annual results, which showed robust growth. Total revenue increased by 16.5% year-on-year to RMB 7.731 billion, with innovative drug revenue surging 27.9% to account for a record 81.5% of total revenue. Net profit attributable to shareholders jumped 86.2%. With ten innovative drugs already on the market and more than five additional candidates nearing approval for launch between 2026 and 2028, the company has laid a solid foundation for sustained future growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147484605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 12:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147484605","market":"hk","top_or_hot":-1,"title":"Stock Track | SIMCERE PHARMA Soars 7.87% in Morning Session on New CEO Appointment and Strong Financial Results","media":"Stock Track","content":"<p>SIMCERE PHARMA's stock soared 7.87% during the morning trading session on Friday, reflecting strong investor confidence in the company's strategic direction.</p><p>The surge follows the company's announcement that Zhou Yunshu, the former Chairman of HENGRUI PHARMA, has officially joined SIMCERE PHARMA as Chief Executive Officer. The company highlighted Zhou's extensive experience in managing domestic pharmaceutical enterprises and his proven track record at HENGRUI PHARMA, where he successfully drove the transition toward innovative drug development.</p><p>Investors were also encouraged by SIMCERE PHARMA's recently released annual results, which showed robust growth. Total revenue increased by 16.5% year-on-year to RMB 7.731 billion, with innovative drug revenue surging 27.9% to account for a record 81.5% of total revenue. Net profit attributable to shareholders jumped 86.2%. With ten innovative drugs already on the market and more than five additional candidates nearing approval for launch between 2026 and 2028, the company has laid a solid foundation for sustained future growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SIMCERE PHARMA Soars 7.87% in Morning Session on New CEO Appointment and Strong Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SIMCERE PHARMA Soars 7.87% in Morning Session on New CEO Appointment and Strong Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 12:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA's stock soared 7.87% during the morning trading session on Friday, reflecting strong investor confidence in the company's strategic direction.</p><p>The surge follows the company's announcement that Zhou Yunshu, the former Chairman of HENGRUI PHARMA, has officially joined SIMCERE PHARMA as Chief Executive Officer. The company highlighted Zhou's extensive experience in managing domestic pharmaceutical enterprises and his proven track record at HENGRUI PHARMA, where he successfully drove the transition toward innovative drug development.</p><p>Investors were also encouraged by SIMCERE PHARMA's recently released annual results, which showed robust growth. Total revenue increased by 16.5% year-on-year to RMB 7.731 billion, with innovative drug revenue surging 27.9% to account for a record 81.5% of total revenue. Net profit attributable to shareholders jumped 86.2%. With ten innovative drugs already on the market and more than five additional candidates nearing approval for launch between 2026 and 2028, the company has laid a solid foundation for sustained future growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1147484605","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147484605","pubTimestamp":1774585375,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SIMCERE PHARMA's stock soared 7.87% during the morning trading session on Friday, reflecting strong investor confidence in the company's strategic direction.The surge follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"个股追踪|先声药业早盘大涨7.87%新CEO上任财报强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"SIMCERE PHARMA's stock soared 7.87% during the morning trading session on Friday, reflecting strong investor confidence in the company's strategic direction.The surge follows the company's announcement that Zhou Yunshu, the former Chairman of HENGRUI PHARMA, has officially joined SIMCERE PHARMA as Chief Executive Officer. The company highlighted Zhou's extensive experience in managing domestic pharmaceutical enterprises and his proven track record at HENGRUI PHARMA, where he successfully drove the transition toward innovative drug development.Investors were also encouraged by SIMCERE PHARMA's recently released annual results, which showed robust growth. Total revenue increased by 16.5% year-on-year to RMB 7.731 billion, with innovative drug revenue surging 27.9% to account for a record 81.5% of total revenue. Net profit attributable to shareholders jumped 86.2%. With ten innovative drugs already on the market and more than five additional candidates nearing approval for launch between 2026 and 2028, the company has laid a solid foundation for sustained future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147484605","isCrawlerRequest":true}